

# Maureen G Maguire

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4430357/publications.pdf>

Version: 2024-02-01

152  
papers

11,208  
citations

57719

44  
h-index

30058

103  
g-index

152  
all docs

152  
docs citations

152  
times ranked

7240  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>New England Journal of Medicine</i> , 2011, 364, 1897-1908.	13.9	2,355
2	Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 1388-1398.	2.5	1,550
3	Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016, 123, 1751-1761.	2.5	541
4	Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2014, 121, 150-161.	2.5	483
5	Risk Factors for Corneal Graft Failure and Rejection in the Collaborative Corneal Transplantation Studies. <i>Ophthalmology</i> , 1994, 101, 1536-1547.	2.5	423
6	Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2013, 120, 122-129.	2.5	268
7	Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2014, 121, 656-666.	2.5	232
8	Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2013, 120, 1860-1870.	2.5	226
9	Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 809-816.	2.5	186
10	n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1681-1690.	13.9	185
11	Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 865-875.	2.5	181
12	Association of psychological and physiological measures of stress in health-care professionals during an 8-week mindfulness meditation program: mindfulness in practice. <i>Stress and Health</i> , 2005, 21, 255-261.	1.4	162
13	Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2017, 124, 97-104.	2.5	158
14	Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2019, 126, 252-260.	2.5	153
15	Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 1846-1853.e5.	2.5	144
16	Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT). <i>Ophthalmology</i> , 2013, 120, 593-599.	2.5	137
17	Myopia and ambient lighting at night. <i>Nature</i> , 1999, 399, 113-114.	13.7	132
18	Risk Factors for Amblyopia in the Vision in Preschoolers Study. <i>Ophthalmology</i> , 2014, 121, 622-629.e1.	2.5	112

#	ARTICLE	IF	CITATIONS
19	Tutorial on Biostatistics: Linear Regression Analysis of Continuous Correlated Eye Data. <i>Ophthalmic Epidemiology</i> , 2017, 24, 130-140.	0.8	108
20	Uncorrected Hyperopia and Preschool Early Literacy. <i>Ophthalmology</i> , 2016, 123, 681-689.	2.5	94
21	Outcomes in Eyes with Retinal Angiomatic Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2016, 123, 609-616.	2.5	93
22	Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 1530-1540.	2.5	92
23	Sustained Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>JAMA Ophthalmology</i> , 2014, 132, 915.	1.4	87
24	Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). <i>Ophthalmology</i> , 2020, 127, 1201-1210.	2.5	87
25	Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab. <i>JAMA Ophthalmology</i> , 2019, 137, 977.	1.4	85
26	Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). <i>Ophthalmology</i> , 2015, 122, 2523-2531.e1.	2.5	84
27	Incidence of Choroidal Neovascularization in the Fellow Eye in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2013, 120, 2035-2041.	2.5	81
28	Tutorial on Biostatistics: Statistical Analysis for Correlated Binary Eye Data. <i>Ophthalmic Epidemiology</i> , 2018, 25, 1-12.	0.8	79
29	Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. <i>American Journal of Ophthalmology</i> , 2018, 195, 93-100.	1.7	77
30	Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. <i>JAMA Ophthalmology</i> , 2020, 138, 1043.	1.4	77
31	Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2019, 137, 382.	1.4	76
32	Prevalence of Vision Disorders by Racial and Ethnic Group among Children Participating in Head Start. <i>Ophthalmology</i> , 2014, 121, 630-636.	2.5	75
33	Postinjection Endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2015, 122, 817-821.	2.5	73
34	Donor, Recipient, and Operative Factors Associated with Graft Success in the Cornea Preservation Time Study. <i>Ophthalmology</i> , 2018, 125, 1700-1709.	2.5	73
35	Effect of Intravitreal Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2383.	3.8	70
36	Sensitivity of Screening Tests for Detecting Vision In Preschoolers-targeted Vision Disorders When Specificity Is 94%. <i>Optometry and Vision Science</i> , 2005, 82, 432-438.	0.6	67

#	ARTICLE	IF	CITATIONS
37	Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2018, 125, 1037-1046.	2.5	60
38	Evaluating Effects of Switching Anti-VEGF Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. <i>JAMA Ophthalmology</i> , 2017, 135, 145.	1.4	56
39	Photographic Assessment of Baseline Fundus Morphologic Features in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2012, 119, 1634-1641.	2.5	53
40	Outer Retinal Tubulation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2014, 121, 2423-2431.	2.5	53
41	<i>VEGFA</i> and <i>VEGFR2</i> Gene Polymorphisms and Response to Anti-VEGF Vascular Endothelial Growth Factor Therapy. <i>JAMA Ophthalmology</i> , 2014, 132, 521.	1.4	53
42	Statin Use and the Incidence of Advanced Age-related Macular Degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. <i>Ophthalmology</i> , 2009, 116, 2381-2385.	2.5	48
43	Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2015, 122, 1203-1211.	2.5	48
44	Outcomes of Eyes with Lesions Composed of >50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>Ophthalmology</i> , 2015, 122, 391-398.e5.	2.5	46
45	Dry Eye Assessment and Management (DREAM) Study: Study design and baseline characteristics. <i>Contemporary Clinical Trials</i> , 2018, 71, 70-79.	0.8	45
46	Poorer Neurodevelopmental Outcomes Associated with Cystoid Macular Edema Identified in Preterm Infants in the Intensive Care Nursery. <i>Ophthalmology</i> , 2015, 122, 610-619.	2.5	42
47	Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. <i>Ophthalmology Retina</i> , 2018, 2, 525-530.	1.2	42
48	Stereoacuity of Preschool Children with and without Vision Disorders. <i>Optometry and Vision Science</i> , 2014, 91, 351-358.	0.6	41
49	Factors Associated With Graft Rejection in the Cornea Preservation Time Study. <i>American Journal of Ophthalmology</i> , 2018, 196, 197-207.	1.7	41
50	Donor, Recipient, and Operative Factors Associated With Increased Endothelial Cell Loss in the Cornea Preservation Time Study. <i>JAMA Ophthalmology</i> , 2019, 137, 185.	1.4	40
51	CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB. <i>Retina</i> , 2018, 38, 1896-1904.	1.0	38
52	Association between Antiplatelet or Anticoagulant Drugs and Retinal or Subretinal Hemorrhage in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2016, 123, 352-360.	2.5	37
53	Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2020, 127, S135-S145.	2.5	36
54	Associations between Hyperopia and Other Vision and Refractive Error Characteristics. <i>Optometry and Vision Science</i> , 2014, 91, 383-389.	0.6	35

#	ARTICLE	IF	CITATIONS
55	Incidence and Outcomes of Positive Donor Rim Cultures and Infections in the Cornea Preservation Time Study. <i>Cornea</i> , 2018, 37, 1102-1109.	0.9	35
56	Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. <i>JAMA Ophthalmology</i> , 2020, 138, 285.	1.4	35
57	Comparison of Optical Coherence Tomography Assessments in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2014, 121, 1956-1965.e2.	2.5	34
58	Calculating Sensitivity, Specificity, and Predictive Values for Correlated Eye Data. , 2020, 61, 29.		34
59	Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management Study. <i>Ophthalmology</i> , 2021, 128, 1384-1392.	2.5	34
60	Climatic and Environmental Correlates of Dry Eye Disease Severity: A Report From the Dry Eye Assessment and Management (DREAM) Study. <i>Translational Vision Science and Technology</i> , 2020, 9, 25.	1.1	33
61	Landmark matching based retinal image alignment by enforcing sparsity in correspondence matrix. <i>Medical Image Analysis</i> , 2014, 18, 903-913.	7.0	32
62	Primary Open-Angle African American Glaucoma Genetics (POAAGG) Study: gender and risk of POAG in African Americans. <i>PLoS ONE</i> , 2019, 14, e0218804.	1.1	32
63	The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline. <i>Translational Vision Science and Technology</i> , 2020, 9, 9.	1.1	31
64	VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 1563-1568.	2.5	29
65	The Dry Eye Assessment and Management (DREAM) extension study – A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. <i>Ocular Surface</i> , 2020, 18, 47-55.	2.2	29
66	Macular OCT Characteristics at 36 Weeks Postmenstrual Age in Infants Examined for Retinopathy of Prematurity. <i>Ophthalmology Retina</i> , 2021, 5, 580-592.	1.2	29
67	Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease. <i>JAMA Ophthalmology</i> , 2019, 137, 767.	1.4	28
68	Postoperative Endothelial Cell Density Is Associated with Late Endothelial Graft Failure after Descemet Stripping Automated Endothelial Keratoplasty. <i>Ophthalmology</i> , 2019, 126, 1076-1083.	2.5	28
69	Intravitreal Pharmacotherapies for Diabetic Macular Edema. <i>Ophthalmology</i> , 2022, 129, 88-99.	2.5	28
70	A Workshop on Measuring the Progression of Atrophy Secondary to Stargardt Disease in the ProgStar Studies: Findings and Lessons Learned. <i>Translational Vision Science and Technology</i> , 2019, 8, 16.	1.1	27
71	Testability of Preschoolers on Stereotests Used to Screen Vision Disorders. <i>Optometry and Vision Science</i> , 2003, 80, 753-757.	0.6	25
72	Retinopathy and Progression of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1217-1224.	2.2	25

#	ARTICLE	IF	CITATIONS
73	Associations of Anisometropia with Unilateral Amblyopia, Interocular Acuity Difference, and Stereoacuity in Preschoolers. <i>Ophthalmology</i> , 2013, 120, 495-503.	2.5	24
74	Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study. <i>Cornea</i> , 2018, 37, 1425-1430.	0.9	24
75	Visual Function of Moderately Hyperopic 4- and 5-Year-Old Children in the Vision in Preschoolers “Hyperopia in Preschoolers Study. <i>American Journal of Ophthalmology</i> , 2016, 170, 143-152.	1.7	23
76	Baseline Visual Field Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease Severity. <i>American Journal of Ophthalmology</i> , 2020, 219, 87-100.	1.7	22
77	Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study. <i>JAMA Ophthalmology</i> , 2022, 140, 392.	1.4	22
78	Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology</i> , 2019, 126, 743-751.	2.5	20
79	Tutorial on Biostatistics: Longitudinal Analysis of Correlated Continuous Eye Data. <i>Ophthalmic Epidemiology</i> , 2021, 28, 3-20.	0.8	20
80	An automated drusen detection system for classifying age-related macular degeneration with color fundus photographs. , 2013, , .		19
81	Effect of Graft Attachment Status and Intraocular Pressure on Descemet Stripping Automated Endothelial Keratoplasty Outcomes in the Cornea Preservation Time Study. <i>American Journal of Ophthalmology</i> , 2019, 203, 78-88.	1.7	19
82	Demographic and Clinical Characteristics Associated with Minimally Invasive Glaucoma Surgery Use. <i>Ophthalmology</i> , 2021, 128, 1292-1299.	2.5	19
83	Attention and Visual Motor Integration in Young Children with Uncorrected Hyperopia. <i>Optometry and Vision Science</i> , 2017, 94, 965-970.	0.6	18
84	Association between Primary Open-Angle Glaucoma and Cognitive Impairment as Measured by the Montreal Cognitive Assessment. <i>Neurodegenerative Diseases</i> , 2018, 18, 315-322.	0.8	18
85	Association of Severity of Dry Eye Disease with Work Productivity and Activity Impairment in the Dry Eye Assessment and Management Study. <i>Ophthalmology</i> , 2021, 128, 850-856.	2.5	18
86	Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen. <i>JAMA Ophthalmology</i> , 2018, 136, 682.	1.4	17
87	Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT. <i>Ophthalmology Retina</i> , 2019, 3, 316-325.	1.2	17
88	Preterm Infant Stress During Handheld Optical Coherence Tomography vs Binocular Indirect Ophthalmoscopy Examination for Retinopathy of Prematurity. <i>JAMA Ophthalmology</i> , 2021, 139, 567.	1.4	17
89	Sporadic Visual Acuity Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). <i>American Journal of Ophthalmology</i> , 2014, 158, 128-135.e10.	1.7	16
90	Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>JAMA Ophthalmology</i> , 2016, 134, 674.	1.4	16

#	ARTICLE	IF	CITATIONS
91	Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy. JAMA Ophthalmology, 2021, 139, 725-733.	1.4	16
92	Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease (from the Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	15
93	Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy. Ophthalmology Retina, 2020, 4, 889-898.	1.2	15
94	Retrospective illumination correction of retinal fundus images from gradient distribution sparsity. , 2012, , .		13
95	Birth Weight Is a Significant Predictor of Retinal Nerve Fiber Layer Thickness at 36 Weeks Postmenstrual Age in Preterm Infants. American Journal of Ophthalmology, 2021, 222, 41-53.	1.7	13
96	Characteristics of Choroidal Neovascularization in the Complications of Age-Related Macular Degeneration Prevention Trial. Ophthalmology, 2008, 115, 1468-1473.e2.	2.5	12
97	Endothelial PAS Domain-Containing Protein 1 (EPAS1) Gene Polymorphisms and Response to Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT). Ophthalmology, 2014, 121, 1663-1664.e1.	2.5	12
98	Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, 123, 858-864.	2.5	12
99	Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. JAMA Ophthalmology, 2020, 138, 510.	1.4	12
100	Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmology, 2021, 139, 1266.	1.4	12
101	Comparison of cycloplegic refraction between Grand Seiko autorefractor and Retinomax autorefractor in the Vision in Preschoolersâ€“Hyperopia in Preschoolers (VIP-HIP) Study. Journal of AAPOS, 2017, 21, 219-223.e3.	0.2	11
102	SYSTEMIC BETA-BLOCKERS AND RISK OF PROGRESSION TO NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 918-925.	1.0	11
103	Association of meibomian gland morphology with symptoms and signs of dry eye disease in the Dry Eye Assessment and Management (DREAM) study. Ocular Surface, 2020, 18, 761-769.	2.2	11
104	Visual and Morphologic Outcomes in Eyes with Hard Exudate in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology Retina, 2017, 1, 25-33.	1.2	10
105	Linking OCT, Angiographic, and Photographic Lesion Components in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 481-493.	1.2	10
106	Non-physician grader reliability in measuring morphological features of the optic nerve head in stereo digital images. Eye, 2019, 33, 838-844.	1.1	10
107	Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole. Ophthalmology, 2021, 128, 1592-1603.	2.5	10
108	Delayed Patchy Choroidal Filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). American Journal of Ophthalmology, 2014, 158, 525-531.e2.	1.7	9

#	ARTICLE	IF	CITATIONS
109	Repeatability and Reproducibility of Axial and Lateral Measurements on Handheld Optical Coherence Tomography Systems Compared with Tabletop System. <i>Translational Vision Science and Technology</i> , 2020, 9, 25.	1.1	9
110	Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>American Journal of Ophthalmology</i> , 2021, 223, 338-347.	1.7	9
111	Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>Ophthalmology Retina</i> , 2021, 5, 962-974.	1.2	9
112	Development and Evaluation of Semiautomated Quantification of Lissamine Green Staining of the Bulbar Conjunctiva From Digital Images. <i>JAMA Ophthalmology</i> , 2017, 135, 1078.	1.4	8
113	Comparison of Donor Cornea Endothelial Cell Density Determined by Eye Banks and by a Central Reading Center in the Cornea Preservation Time Study. <i>Cornea</i> , 2019, 38, 426-432.	0.9	8
114	A Review of Studies of the Association of Vision-Related Quality of Life with Measures of Visual Function and Structure in Patients with Glaucoma in the United States. <i>Ophthalmic Epidemiology</i> , 2021, 28, 265-276.	0.8	8
115	Associations between visual function and magnitude of refractive error for emmetropic to moderately hyperopic 4- and 5-year-old children in the Vision in Preschoolers - Hyperopia in Preschoolers Study. <i>Ophthalmic and Physiological Optics</i> , 2021, 41, 553-564.	1.0	8
116	Tutorial on Biostatistics: Receiver-Operating Characteristic (ROC) Analysis for Correlated Eye Data. <i>Ophthalmic Epidemiology</i> , 2022, 29, 117-127.	0.8	8
117	Conjunctival HLA-DR Expression and Its Association With Symptoms and Signs in the DREAM Study. <i>Translational Vision Science and Technology</i> , 2019, 8, 31.	1.1	7
118	Prevalence of Novel Candidate Sjögren Syndrome Autoantibodies in the Penn Sjögren's International Collaborative Clinical Alliance Cohort. <i>Cornea</i> , 2019, 38, 1500-1505.	0.9	7
119	Association between pseudodrusen and delayed patchy choroidal filling in the comparison of age-related macular degeneration treatments trials. <i>Acta Ophthalmologica</i> , 2017, 95, e518-e520.	0.6	6
120	Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2019, 137, 1306.	1.4	6
121	Effects of Omega-3 Supplementation on Exploratory Outcomes in the Dry Eye Assessment and Management Study. <i>Ophthalmology</i> , 2020, 127, 136-138.	2.5	6
122	Primary orbital melanoma: A report of a case and comprehensive review of the literature. <i>Orbit</i> , 2021, 40, 461-469.	0.5	6
123	SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021, 41, 1455-1462.	1.0	6
124	Detection of Significant Hyperopia in Preschool Children Using Two Automated Vision Screeners. <i>Optometry and Vision Science</i> , 2022, 99, 114-120.	0.6	6
125	Corneal surface area: an index of anterior segment growth. <i>Ophthalmic and Physiological Optics</i> , 2001, 21, 286-295.	1.0	5
126	Why DREAM should make you think twice about recommending Omega-3 supplements. <i>Ocular Surface</i> , 2019, 17, 617-618.	2.2	5



#	ARTICLE	IF	CITATIONS
127	Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5. <i>JAMA Ophthalmology</i> , 2020, 138, 276.	1.4	5
128	Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial. <i>Translational Vision Science and Technology</i> , 2021, 10, 3.	1.1	5
129	Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. <i>Ophthalmology Retina</i> , 2022, 6, 771-785.	1.2	5
130	reply: Myopia and ambient night-time lighting. <i>Nature</i> , 2000, 404, 144-144.	13.7	4
131	Prelamellar Dissection Donor Corneal Thickness Is Associated With Descemet Stripping Automated Endothelial Keratoplasty Operative Complications in the Cornea Preservation Time Study. <i>Cornea</i> , 2019, 38, 1069-1076.	0.9	4
132	Auditory and olfactory findings in patients with USH2A -related retinal degeneration" Findings at baseline from the rate of progression in USH2A -related retinal degeneration natural history study ( ) Tj ETQq0 0 OugBT/Overlock 10 TF		
133	A New Screening Questionnaire to Identify Patients With Dry Eye With a High Likelihood of Having Sjögren Syndrome. <i>Cornea</i> , 2021, 40, 179-187.	0.9	4
134	ASSOCIATION OF DIAGNOSIS CODE-BASED AND LABORATORY RESULTS-BASED KIDNEY FUNCTION WITH DEVELOPMENT OF VISION THREATENING DIABETIC RETINOPATHY. <i>Ophthalmic Epidemiology</i> , 2020, 27, 498-503.	0.8	3
135	Prevalence and Factors Associated with Optic Disc Tilt in the Primary Open-Angle African American Glaucoma Genetics Study. <i>Ophthalmology Glaucoma</i> , 2022, 5, 544-553.	0.9	3
136	Integrated Visualization Highlighting Retinal Changes in Retinopathy of Prematurity From 3-Dimensional Optical Coherence Tomography Data. <i>JAMA Ophthalmology</i> , 2022, 140, 725.	1.4	3
137	Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials. <i>JAMA Ophthalmology</i> , 2015, 133, 726.	1.4	2
138	ASSOCIATION BETWEEN ORAL IRON SUPPLEMENTATION AND RETINAL OR SUBRETINAL HEMORRHAGE IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS. <i>Retina</i> , 2019, 39, 1965-1972.	1.0	2
139	Another Disappointment for $\omega$ -3 Fatty Acid and Dry Eye Disease. <i>JAMA Ophthalmology</i> , 2022, 140, 714.	1.4	2
140	Understanding Variation in Response to Anti-vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2018, 136, 884.	1.4	1
141	BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. <i>Retina</i> , 2021, 41, 125-134.	1.0	1
142	Tobacco counseling in the setting of thyroid eye disease. <i>Arquivos Brasileiros De Oftalmologia</i> , 2022, 85, 13-18.	0.2	1
143	Phase 4 Studies on Phosphodiesterase 5 Inhibitors. <i>JAMA Ophthalmology</i> , 2022, 140, 484.	1.4	1
144	Cost-Related Motivations for Research. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 847.	3.8	0

#	ARTICLE	IF	CITATIONS
145	Author reply. <i>Ophthalmology</i> , 2014, 121, e44-e45.	2.5	0
146	Reply. <i>Ophthalmology</i> , 2017, 124, e33.	2.5	0
147	Further Scrutiny of Vision Outcomes When Aflibercept Is Used as Rescue Treatment for Eyes With Diabetic Macular Edema Treated With Laser. <i>JAMA Ophthalmology</i> , 2017, 135, 114.	1.4	0
148	Updated Methods for Assessing the Risk of Progression to Late Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2019, 137, 745.	1.4	0
149	Steps Forward in Analyzing Optical Coherence Tomography in Age-Related Macular Degeneration—Capitalizing on the Power of Artificial Intelligence. <i>JAMA Ophthalmology</i> , 2020, 138, 747.	1.4	0
150	Dose Response in Anti-VEGF Treatment for Neovascular Age-related Macular Degeneration. <i>Retina</i> , 2021, Publish Ahead of Print, 1141-1142.	1.0	0
151	Best Practices for the Design of Clinical Trials Related to the Visual System. <i>Annual Review of Vision Science</i> , 2021, 7, 867-886.	2.3	0
152	Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. <i>British Journal of Ophthalmology</i> , 2023, 107, 1000-1006.	2.1	0